Details

Autor(en) / Beteiligte

• NILSSON, B
• SJÖLUND, K
• KINDBLOM, L.-G
• MEIS-KINDBLOM, J. M
• BUMMING, P
• NILSSON, O
• ANDERSSON, J
• AHLMAN, H

Titel

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

Ist Teil von

• British journal of cancer, 2007-06, Vol.96 (11), p.1656-1658

Ort / Verlag

Basingstoke: Nature Publishing Group

Erscheinungsjahr

2007

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of patients with high-risk tumours (n=23) was compared with historic controls (n=48) who were treated with surgery alone. The mean follow-up period was over 3 years in both groups. Only 1 out of 23 patients (4%) in the adjuvant treatment group developed recurrent disease compared to 32 out of 48 patients (67%) in the control group. This preliminary study indicates that 1 year of adjuvant treatment with imatinib dramatically improves recurrence-free survival. Confirmation of these findings awaits the results of ongoing randomised studies.